Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology.
The advent of positron emission tomography (PET) and PET/computed tomography (CT) now enables us to detect metabolically active gynecologic cancers with greater accuracy than was possible with anatomic imagings. Fluorine-18 fluorodeoxyglucose PET has been useful in differentiation of malignant from benign lymph nodes, and residual or recurrent cancers from post-treatment changes. PET/CT produces additional information for the diagnosis and tissue biopsy as well as radiotherapy planning. This paper reviews the principle and clinical utility of PET and PET/CT in the diagnosis, staging, recurrence, therapeutic response as well as prognosis of gynecologic cancers.
Kim
E E
EE
Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA. ekim@di.mdacc.tmc.edu
D005260:Female; D019788:Fluorodeoxyglucose F18; D005831:Genital Diseases, Female / Q000175:diagnosis* / Q000000981:diagnostic imaging; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18